Dishman Carbogen Amcis Ltd Share Price & Stock Analysis

Dishman Carbogen Amcis Ltd (NSE: DCAL, BSE: 540701) is an Ahmedabad, Gujarat-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹2,744 Cr, it ranks #1,095 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 11 in Pharmaceutical CDMO and CRO Services. At ₹117.20 (as of 19 Nov 2026), the share price is 57.3% below its 52-week high of ₹274.30 and 0.5% above its 52-week low of ₹116.60. The share price is down 51.8% over one year and down 31.2% over three months.

Key Metrics

Current Price₹117.20
Market Cap₹2,744 Cr
NSE SymbolDCAL
BSE Code540701
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services > Pharmaceutical CDMO and CRO Services
P/E Ratio28
Return on Equity1.56%
Return on Assets1.34%
52-Week Range₹116.60 – ₹274.30
1-Year Price Change-51.8%
3-Month Price Change-31.2%
Beta (1Y)0.32
Dividend Yield0.00%
HeadquartersAhmedabad, Gujarat
Websiteimdcal.com

Latest Quarterly Results — Q2 FY27

Revenue₹507 Cr
Net Profit₹-67 Cr
Net Margin-13.2%
EPS (Basic)₹-4.26
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Dishman Carbogen Amcis Ltd Quarterly Revenue and Profit Trend

Dishman Carbogen Amcis Ltd reported revenue of ₹507 Cr in Q2 FY27, down 22.3% from ₹653 Cr in Q2 FY26 and down 25.1% from ₹678 Cr in Q1 FY27. It posted a net loss of ₹67 Cr for the quarter, against a net profit of ₹65 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹507 Cr (Q2 FY27) to ₹851 Cr (Q4 FY26). The company reported a net loss in 3 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹507 Cr−₹67 Cr−13.2%
Q1 FY27₹678 Cr−₹58 Cr−8.5%
Q4 FY26₹851 Cr₹22 Cr2.6%
Q3 FY26₹720 Cr−₹13 Cr−1.8%
Q2 FY26₹653 Cr₹65 Cr10.0%
Q1 FY26₹708 Cr₹23 Cr3.3%
Q4 FY25₹716 Cr₹43 Cr6.0%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 59.32% of Dishman Carbogen Amcis Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 48.3% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).

About Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

Products and Services

1. Contract Research and Manufacturing Services (CRAMS)-This segment provides pharmaceutical contract research and manufacturing services. 2. Vitamin-D, Bulk Drugs, Quats, Speciality Chemicals and Traded Goods-This segment manufactures and distributes vitamin D analogues, cholesterol, bulk drugs, intermediates, and quats and specialty chemicals. 3. Unallocated/Others-0 4. Segment Adjustment-0

Business Segments

1. Medical Labs & Research-100%

Dishman Carbogen Amcis Ltd vs Peers — Pharmaceutical CDMO and CRO Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Divis Laboratories Limited₹3,01,758 Cr118.416.19%₹3,676 Cr+69.5%
Anthem Biosciences Limited₹53,926 Cr90.119.45%₹594 Cr+34.3%
Sai Life Sciences Limited₹40,755 Cr116.115.13%₹659 Cr+105.6%
Onesource Specialty Pharma Limited₹18,138 Crn/m-1.26%₹516 Cr-8.2%
Cohance Lifesciences Ltd₹17,756 Cr100.65.11%₹477 Cr-26.9%
Syngene International Ltd.₹17,630 Cr56.96.62%₹833 Cr-34.1%
Jubilant Pharmova Ltd₹15,556 Cr39.15.96%₹2,370 Cr-16.9%
Concord Biotech Ltd₹12,495 Cr24.213.54%₹309 Cr-23.7%
Dishman Carbogen Amcis Ltd₹2,744 Cr281.56%₹507 Cr-51.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Dishman Carbogen Amcis Ltd?

Dishman Carbogen Amcis Ltd is trading at ₹117.20, with a market capitalisation of ₹2,744 Cr.

Which sector does Dishman Carbogen Amcis Ltd belong to?

Dishman Carbogen Amcis Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).

What are the key financial ratios of Dishman Carbogen Amcis Ltd?

Dishman Carbogen Amcis Ltd has a P/E of 28 and a return on equity of 1.56%.

What is the stock symbol of Dishman Carbogen Amcis Ltd?

Dishman Carbogen Amcis Ltd is listed on the NSE under the symbol DCAL and on the BSE under the scrip code 540701.

How has Dishman Carbogen Amcis Ltd's share price moved over the past year?

Dishman Carbogen Amcis Ltd's share price is down 51.8% over one year and down 31.2% over three months. Its 52-week range is ₹116.60 to ₹274.30.

What were Dishman Carbogen Amcis Ltd's latest quarterly results?

In Q2 FY27, Dishman Carbogen Amcis Ltd reported revenue of ₹507 Cr and net profit of ₹-67 Cr, with basic EPS of ₹-4.26 (consolidated, parsed from the company's exchange filing).

How have Dishman Carbogen Amcis Ltd's revenue and profit changed over the past year?

Dishman Carbogen Amcis Ltd reported revenue of ₹507 Cr in Q2 FY27, down 22.3% from ₹653 Cr in Q2 FY26 and down 25.1% from ₹678 Cr in Q1 FY27.

What is the promoter holding in Dishman Carbogen Amcis Ltd?

Promoters held 59.32% of Dishman Carbogen Amcis Ltd's shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 19 Nov 2026. Descriptive market data only — not investment advice.